GLP-1 Receptor Agonists: Tailoring Treatment to Account for Diversity in Obesity Management
核心洞察
Clinical trials reveal that GLP-1RAs, effective for diabetes (搜索) and obesity (搜索), show variable weight loss across different demographics, highlighting the need for precision-based approaches.
The SURMOUNT-CN trial indicated that Chinese adults experienced a weight loss plateau earlier than predominantly white populations in SURMOUNT-1, suggesting BMI and ethnic-specific dosing adjustments are necessary.
Research suggests age-based tailoring of GLP-1RA treatment could improve outcomes, with trials showing varying efficacy in children versus adolescents, warranting further exploration of age-specific regimens.
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are emerging as versatile treatment options beyond diabetes (搜索) and obesity (搜索), prompting a critical examination of how genetic, clinical, and sociodemographic differences influence their effectiveness, particularly in weight loss. Recent clinical trials, including SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF-DM, have underscored the significance of GLP-1RAs in managing diabetes, obesity, and related metabolic conditions. However, the broad deployment of these drugs raises concerns about the limited representation of diverse populations in clinical trials, potentially affecting treatment outcomes.
Discrepancies in Weight Loss Across Diverse Populations
The SELECT trial, which included a diverse participant pool, demonstrated that semaglutide, a GLP-1RA, led to clinically meaningful weight loss over 208 weeks. Despite overall significant weight loss, subgroup analyses based on self-reported race, sex, and BMI revealed notable discrepancies. Women, on average, experienced greater weight loss than men, while individuals of Asian descent showed smaller reductions. These variations may be linked to differing BMI classes within these subgroups. The trial's limitation lies in the insufficient representation within racial subgroups, which can lead to misleading results.
Ethnic and BMI-Based Considerations
The SURMOUNT-CN trial, which assessed tirzepatide in Chinese adults, reported significant weight loss, aligning with results from other SURMOUNT trials primarily conducted in white populations. However, weight loss in the SURMOUNT-CN study plateaued at week 44, whereas in SURMOUNT-1, body weight continued to decrease for 72 weeks. These differences are attributed to variations in BMI cutoffs and the proportion of female participants. Given that BMI thresholds for obesity (搜索) differ across ethnicities, such as Chinese adults having lower BMI thresholds than European-descent populations, the efficacy of GLP-1RA doses can vary. These findings emphasize the importance of tailoring GLP-1RA trials to address sex- and BMI-based differences in diverse ethnic groups.
Age-Related Treatment Tailoring
Age-based tailoring of GLP-1RA treatment may also enhance clinical outcomes. Studies indicate that rapid weight gain in adolescents with obesity (搜索) typically occurs between ages 2 and 6, suggesting a need to reevaluate the timing of GLP-1RA treatment initiation and continuation. A long-term weight-management trial involving children aged 6 to 12 found that liraglutide was more effective than placebo in reducing body weight and BMI. Children showed a larger treatment difference compared to adolescents, though both groups experienced BMI increases after discontinuing pharmacotherapy. These observations underscore the need for further research into dose responses, treatment regimens, and durations tailored to each age group to maximize efficacy and minimize side effects.
Expanding Utility and Comorbidity Considerations
Major trials evaluating the impact of GLP-1RAs on cardiovascular, kidney, and liver outcomes have indicated that the benefits of these drugs may extend beyond weight loss. As the use of GLP-1RAs expands to treat diseases beyond obesity (搜索), considering comorbidities when prescribing these drugs for weight loss is crucial for providing tailored healthcare. The risk of comorbidities varies based on age, sex, and ethnicity, reinforcing the need for clinical trials designed specifically for distinct risk stratification, thereby reducing reliance on post hoc and underpowered subgroup analyses.
While GLP-1RAs hold immense potential in treating various non-communicable diseases, there is a need for more comprehensive data on their treatment benefits and adverse outcomes that reflect the real-world diversity of populations. Addressing these concerns requires well-designed clinical trials that prioritize diverse participants and include extended follow-up periods. Until these knowledge gaps are filled, the widespread deployment of these drugs for weight loss should proceed cautiously.